Malignant Pleural Mesothelioma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MLG079 MIFTS: 46	Malignant Pleural Mesothelioma Categories: Cancer diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Malignant Pleural Mesothelioma

MalaCards integrated aliases for Malignant Pleural Mesothelioma:

Name: Malignant Pleural Mesothelioma ¹² ³⁷ ¹⁵ ⁷³

Malignant Mesothelioma of Pleura ¹²

Pleural Malignant Mesothelioma ⁵⁵

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms of mesothelial and soft tissue

Mesothelioma

Mesothelioma of pleura

External Ids:

Disease Ontology ¹² DOID:7474

ICD10 ³³ C45.0

NCIt ⁵⁰ C7376

SNOMED-CT ⁶⁸ 109373004 187878009 254645002

KEGG ³⁷ H00015

UMLS ⁷³ C0812413

Sources

Summaries for Malignant Pleural Mesothelioma

Disease Ontology : ¹² A pleural cancer that has material basis in mesothelium cells.

MalaCards based summary : Malignant Pleural Mesothelioma, also known as malignant mesothelioma of pleura, is related to mesothelioma, malignant and sarcomatoid mesothelioma, and has symptoms including chest pain, dyspnea and fatigue. An important gene associated with Malignant Pleural Mesothelioma is PVT1 (Pvt1 Oncogene
Our results suggest that C-MYC and PVT1 CNG promotes a malignant phenotype of MPM,with C-MYC CNG stimulating cell proliferation and PVT1 both stimulating proliferation and inhibiting apoptosis.
Dysfunction Pattern: Regulation [up-regulated]), and among its related pathways/superpathways is FGF signaling pathway. The drugs Alimta and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and endothelial, and related phenotype is normal.

Sources

Related Diseases for Malignant Pleural Mesothelioma

Diseases in the Benign Pleural Mesothelioma family:

Malignant Pleural Mesothelioma

Diseases related to Malignant Pleural Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 83)

#	Related Disease	Score	Top Affiliating Genes
1	mesothelioma, malignant	30.8	BAP1 CALB2 CDH2 MSLN NKX2-1 SPP1
2	sarcomatoid mesothelioma	30.4	NKX2-1 THBD WT1
3	lung cancer susceptibility 3	29.7	CALB2 GAS5 MET MSLN NKX2-1
4	renal cell carcinoma, nonpapillary	29.4	GAS5 MET NKX2-1 PVT1 WT1
5	pancreatic cancer	28.4	BIRC5 ENSG00000261211 GAS5 MET MSLN PVT1
6	lung cancer	27.5	BIRC5 GAS5 MET NKX2-1 PVT1 SNHG7
7	fallopian tube carcinosarcoma	10.8	CALB2 WT1
8	mucinous bronchioloalveolar adenocarcinoma	10.7	CALB2 NKX2-1
9	venous hemangioma	10.7	CALB2 WT1
10	lymphohistiocytoid mesothelioma	10.6	CALB2 THBD
11	malignant epithelial mesothelioma	10.6	THBD WT1
12	peritoneum cancer	10.6	BAP1 WT1
13	pericardium cancer	10.5	CALB2 MSLN THBD
14	rete testis adenocarcinoma	10.5	CALB2 NKX2-1 THBD
15	pericardial mesothelioma	10.5	CALB2 MSLN THBD
16	adenomatoid tumor	10.5	CALB2 THBD WT1
17	rete testis neoplasm	10.5	CALB2 NKX2-1 THBD
18	peritoneal mesothelioma	10.4	BAP1 THBD WT1
19	spindle cell liposarcoma	10.4	CALB2 WT1
20	ovarian brenner tumor	10.4	CALB2 THBD WT1
21	sertoli-leydig cell tumor	10.3	CALB2 WT1
22	malignant biphasic mesothelioma	10.3	CALB2 MSLN THBD WT1
23	kidney cancer	10.2	GAS5 MET PVT1
24	adenocarcinoma	10.2
25	endotheliitis	10.2
26	thyroid cancer, nonmedullary, 1	10.1	GAS5 NKX2-1 PVT1
27	adamantinoma of long bones	10.1	BIRC5 GAS5 PVT1 SPP1
28	clear cell renal cell carcinoma	10.1	BIRC5 MET PVT1
29	sertoli cell tumor	10.1	CALB2 WT1
30	pneumothorax, primary spontaneous	10.1
31	small cell cancer of the lung	10.1
32	pneumothorax	10.1
33	mediastinitis	10.1
34	pleural cancer	10.0	BAP1 CALB2 MSLN SPP1 TYMS WT1
35	benign mesothelioma	10.0	CALB2 NKX2-1 THBD TYMS WT1
36	esophageal cancer	10.0
37	wilms tumor 5	10.0
38	wilms tumor 6	10.0
39	asbestosis	10.0
40	sarcoma	10.0
41	esophagitis	10.0
42	squamous cell carcinoma	10.0
43	cervicitis	10.0
44	breast cancer	9.8
45	intussusception	9.8
46	scleroderma, familial progressive	9.8
47	wilms tumor 1	9.8
48	ataxia-telangiectasia	9.8
49	lymphoma, hodgkin, classic	9.8
50	cervical cancer	9.8

Graphical network of the top 20 diseases related to Malignant Pleural Mesothelioma:

Sources

Symptoms & Phenotypes for Malignant Pleural Mesothelioma

UMLS symptoms related to Malignant Pleural Mesothelioma:

chest pain, dyspnea, fatigue, chills, malaise

MGI Mouse Phenotypes related to Malignant Pleural Mesothelioma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	normal	MP:0002873	9.23	BIRC5 CALB2 MET MSLN NKX2-1 THBD

Sources

Drugs & Therapeutics for Malignant Pleural Mesothelioma

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Alimta ¹⁸ ⁴⁹	PEMETREXED (also Pemetrexed Disodium)	Eli Lilly	February 2004
FDA Label: Alimta Disease/s that Drug Treats:Mesothelioma Indications and Usage: ¹⁸ ALIMTAÂ® is a folate analog metabolic inhibitor indicated for: Locally Advanced or Metastatic Nonsquamous Non-Small CellLung Cancer: Initial treatment in combination with cisplatin. (1.1) Maintenance treatment of patients whose disease has notprogressed after four cycles of platinum-based first-linechemotherapy. (1.2) After prior chemotherapy as a single-agent. (1.3) Mesothelioma: in combination with cisplatin. (1.4)Limitations of Use: ALIMTA is not indicated for the treatment of patients withsquamous cell non-small cell lung cancer. (1.5) DrugBank Targets: ¹⁶ 1. Thymidylate synthase;2. Bifunctional purine biosynthesis protein PURH;3. Dihydrofolate reductase;4. Trifunctional purine biosynthetic protein adenosine-3 Mechanism of Action: ¹⁸ Target: folic acid/ thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase Action: antagonist/ inhibitor FDA: ALIMTA, pemetrexed for injection, is a folate analog metabolic inhibitor that exerts its action by disrupting folatedependentmetabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibitsthymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT),which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides.Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate bindingprotein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzymefolylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT.Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, is thought to occur to alesser extent, in normal tissues. Polyglutamated metabolites are thought to have an increased intracellular half-liferesulting in prolonged drug action in malignant cells.

Drugs for Malignant Pleural Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 181)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Gemcitabine

Approved

Phase 3,Phase 2,Phase 1

95058-81-4

60750

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

84093 441203 2767

Doxorubicin

Approved, Investigational

Phase 3,Phase 2

23214-92-8

31703

Vinblastine

Approved

Phase 3,Phase 2,Phase 1

865-21-4

13342 241903

Hydroxocobalamin

Approved

Phase 2, Phase 3,Phase 3

13422-51-0

11953898 44475014

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3,Phase 2,Phase 1

50-02-2

5743

Vinorelbine

Approved, Investigational

Phase 3,Phase 2,Phase 1

71486-22-1

60780 44424639

Pemetrexed

Approved, Investigational

Phase 3,Phase 2,Phase 1

150399-23-8, 137281-23-3

446556 60843

Carboplatin

Approved

Phase 3,Phase 2,Phase 1

41575-94-4

10339178 498142 38904

Vincristine

Approved, Investigational

Phase 3

2068-78-2, 57-22-7

5978

Raltitrexed

Approved, Investigational

Phase 3,Phase 1,Phase 2

112887-68-0

104758

Vorinostat

Approved, Investigational

Phase 3,Phase 1,Phase 2

149647-78-9

5311

Bevacizumab

Approved, Investigational

Phase 2, Phase 3,Phase 1

216974-75-3

nivolumab

Approved

Phase 3,Phase 2

946414-94-4

Pembrolizumab

Approved

Phase 3,Phase 1,Phase 2

1374853-91-4

Nintedanib

Approved

Phase 3,Phase 2

656247-17-5

56843413

leucovorin

Approved, Nutraceutical

Phase 3,Phase 2,Phase 1

58-05-9

143 6006

Methylcobalamin

Approved, Experimental, Investigational, Nutraceutical

Phase 2, Phase 3,Phase 3

13422-55-4

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2,Phase 1

59-30-3

6037

Cyanocobalamin

Approved, Nutraceutical

Phase 2, Phase 3,Phase 3

68-19-9

44176380

Doxil

Approved June 1999

Phase 3,Phase 2

31703

Dexamethasone acetate

Phase 3,Phase 2,Phase 1

1177-87-3

Analgesics

Phase 3,Phase 2,Phase 1

Micronutrients

Phase 3,Phase 2

Folic Acid Antagonists

Phase 3,Phase 2,Phase 1

Gastrointestinal Agents

Phase 3,Phase 2,Phase 1

Trace Elements

Phase 3,Phase 2

Nucleic Acid Synthesis Inhibitors

Phase 3,Phase 2,Phase 1

Vitamin B 12

Phase 2, Phase 3,Phase 3

Peripheral Nervous System Agents

Phase 3,Phase 2,Phase 1

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1

Vitamin B Complex

Phase 3,Phase 2,Phase 1

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1

Vitamins

Phase 2, Phase 3,Phase 3

Antibodies

Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 3,Phase 2,Phase 1

Antibodies, Monoclonal

Phase 3,Phase 2,Phase 1

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1

Anti-Infective Agents

Phase 3,Phase 2,Phase 1

Antiemetics

Phase 3,Phase 2,Phase 1

BB 1101

Phase 3,Phase 2,Phase 1

Antimetabolites

Phase 3,Phase 2,Phase 1

Antiviral Agents

Phase 3,Phase 2,Phase 1

Autonomic Agents

Phase 3,Phase 2,Phase 1

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1

Antimitotic Agents

Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1

Alkylating Agents

Phase 3,Phase 2,Phase 1

Mitomycins

Phase 3

Histone Deacetylase Inhibitors

Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 194)

#	Name	Status	NCT ID	Phase	Drugs
1	NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed	Completed	NCT01098266	Phase 3	NGR-hTNF plus Best Investigator's Choice (BIC);Placebo plus Best Investigator's Choice (BIC)
2	Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)	Completed	NCT00128102	Phase 3	vorinostat;Placebo
3	Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma	Completed	NCT00075699	Phase 3	cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
4	Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery	Completed	NCT00005636	Phase 3	cisplatin;pemetrexed disodium
5	Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura	Completed	NCT00004920	Phase 3	cisplatin;raltitrexed
6	A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma	Completed	NCT00190762	Phase 3	Pemetrexed
7	Mesothelioma Avastin Plus Pemetrexed-cisplatin Study	Completed	NCT00651456	Phase 2, Phase 3	Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
8	Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2	Completed	NCT01836575	Phase 3	Pemetrexed;Carboplatin
9	Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin	Recruiting	NCT02709512	Phase 2, Phase 3	ADI-PEG 20 plus Pem Cis
10	PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma	Active, not recruiting	NCT02991482	Phase 3	Pembrolizumab;Gemcitabine;Vinorelbine
11	Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients	Active, not recruiting	NCT02899299	Phase 3	Pemetrexed;Cisplatin;Carboplatin
12	Nintedanib (BIBF 1120) in Mesothelioma	Active, not recruiting	NCT01907100	Phase 3	Nintedanib;Pemetrexed;Cisplatin;Cisplatin;Pemetrexed;Placebo
13	PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma	Terminated	NCT01604005	Phase 3
14	A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma	Unknown status	NCT01279967	Phase 2	ADI-PEG 20
15	Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma	Unknown status	NCT01358084	Phase 2	NGR-hTNF;Placebo
16	Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma	Unknown status	NCT00886028	Phase 2	Liposomal doxorubicin;Cisplatin
17	Trimodal Lung-Sparing Treatment of Pleural Mesothelioma	Unknown status	NCT00859495	Phase 2	Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
18	Four Versus Six Cycles of Pemetrexed/Platinum for MPM	Unknown status	NCT02497053	Phase 2	pemetrexed/platinum chemotherapy;Pemetrexed/platinum chemotherapy
19	Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma	Unknown status	NCT00354393	Phase 2	cisplatin;methotrexate;vinorelbine ditartrate
20	A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma	Unknown status	NCT01569919	Phase 2	Pemetrexed;Cisplatin;Dexamethasone
21	A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)	Unknown status	NCT02588131	Phase 2	tremelimumab plus MEDI4736
22	A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma	Unknown status	NCT01649024	Phase 2	Tremelimumab
23	The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma	Unknown status	NCT01655888	Phase 2	Tremelimumab
24	Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma	Unknown status	NCT00996385	Phase 2	Velcade (bortezomib) plus Eloxatin (oxaliplatin)
25	Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma	Unknown status	NCT01281800	Phase 2
26	Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.	Completed	NCT01721018	Phase 1, Phase 2
27	Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma	Completed	NCT00386815	Phase 2	pemetrexed;cisplatin
28	Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment	Completed	NCT01243632	Phase 2	Prolonged 6-hr infusion of gemcitabine
29	A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma	Completed	NCT01486368	Phase 2	PF-03446962
30	Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma	Completed	NCT00484276	Phase 2	NGR-hTNF
31	Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity	Completed	NCT01024946	Phase 2	everolimus
32	Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma	Completed	NCT00272558	Phase 2	Carboplatin and Vinorelbine
33	Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma	Completed	NCT02662504	Phase 2	Adjuvant chemotherapy
34	Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy	Completed	NCT01265433	Phase 2
35	Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)	Completed	NCT00700336	Phase 1, Phase 2	pemetrexed, cisplatin and CBP501;pemetrexed and cisplatin
36	Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma	Completed	NCT01112293	Phase 2	GC1008
37	Pazopanib in Treating Patients With Malignant Pleural Mesothelioma	Completed	NCT00459862	Phase 2	pazopanib hydrochloride
38	Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma	Completed	NCT00251550	Phase 1, Phase 2	Pemetrexed;Cisplatin
39	Bortezomib in Treating Patients With Malignant Pleural Mesothelioma	Completed	NCT00513877	Phase 2	bortezomib
40	S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery	Completed	NCT00243074	Phase 2	cediranib maleate
41	An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma	Completed	NCT00738582	Phase 2	MORAb-009 (Amatuximab);Pemetrexed;Cisplatin
42	Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma	Completed	NCT00227630	Phase 2	cisplatin;pemetrexed disodium
43	Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma	Completed	NCT00392444	Phase 2	sunitinib malate
44	Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma	Completed	NCT00407459	Phase 2	Bevacizumab, Pemetrexed, Carboplatin
45	Nivolumab in Patients With Recurrent Malignant Mesothelioma	Completed	NCT02497508	Phase 2	nivolumab
46	S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery	Completed	NCT00770120	Phase 2	everolimus
47	A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.	Completed	NCT00996567	Phase 2	Cetuximab (Erbitux)
48	Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma	Completed	NCT00004033	Phase 2	liposomal NDDP
49	Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma	Completed	NCT00101283	Phase 2	pemetrexed disodium;gemcitabine hydrochloride;carboplatin
50	Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate	Completed	NCT00165516	Phase 2	Cisplatin;Sodium Thiosulfate

Search NIH Clinical Center for Malignant Pleural Mesothelioma

Sources

Genetic Tests for Malignant Pleural Mesothelioma

Sources

Anatomical Context for Malignant Pleural Mesothelioma

MalaCards organs/tissues related to Malignant Pleural Mesothelioma:

⁴¹

Lung, T Cells, Endothelial, Testes, Liver, Thymus, Lymph Node

Sources

Publications for Malignant Pleural Mesothelioma

Articles related to Malignant Pleural Mesothelioma:

(show top 50) (show all 869)

#	Title	Authors	Year
1	Correction: Apoptosis by [Pt(O,O'-acac)(I^-acac)(DMS)] requires PKC-I' mediated p53 activation in malignant pleural mesothelioma. ( 29432478 )	Muscella A....Marsigliante S.	2018
2	Expression analysis of High-mobility group box-1 (HMGB1) in histologic samples of malignant pleural mesothelioma. ( 29356044 )	Rrapaj E....Boldorini R.L.	2018
3	Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma. ( 29362358 )	Sato H....Toyooka S.	2018
4	British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. ( 29444986 )	Woolhouse I....Maskell N.A.	2018
5	Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma. ( 29946373 )	Bensaid D....Blanquart C.	2018
6	PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma. ( 29908324 )	Quispel-Janssen J....Baas P.	2018
7	Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study. ( 29967955 )	Gudmundsson E....Armato S.G.	2018
8	Current surgical treatment of malignant pleural mesothelioma. ( 29980443 )	Chihara K.	2018
9	Prostate-specific membrane antigen avidity on positron emission tomography scan in malignant pleural mesothelioma. ( 29873168 )	Ekanayake S.K.D.M....Lee J.C.	2018
10	Multiple intracranial metastases from postoperative giant sarcomatoid malignant pleural mesothelioma: A case report and literature review. ( 29387394 )	Tian D....Fu M.	2018
11	Radical multimodality therapy for malignant pleural mesothelioma. ( 29309720 )	Abdel-Rahman O....Eltobgy M.	2018
12	An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. ( 29438360 )	Linton A....Reid G.	2018
13	FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients. ( 29876617 )	Incerti E....Picchio M.	2018
14	Biomarkers in malignant pleural mesothelioma: current status and future directions. ( 29850181 )	Ahmadzada T....Kao S.	2018
15	Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival. ( 29413055 )	Paajanen J....Vehmas T.	2018
16	A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol. ( 29853412 )	Fujimoto N....Hotta K.	2018
17	Critical role of the Ror-family of receptor tyrosine kinases in invasion and proliferation of malignant pleural mesothelioma cells. ( 29845703 )	Saji T....Minami Y.	2018
18	Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma. ( 29931180 )	Gill R.R....Richards W.G.	2018
19	Heterogeneity in Malignant Pleural Mesothelioma. ( 29848954 )	Oehl K....Meerang M.	2018
20	Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. ( 29346042 )	Kindler H.L....Hassan R.	2018
21	Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. ( 29313814 )	Tsao A.S....Hong W.K.	2018
22	Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on. ( 29914087 )	Ledda C....Rapisarda V.	2018
23	The management of malignant pleural mesothelioma in the USA 2004-13-a decade of lost opportunity? ( 29849196 )	Waller D.A.	2018
24	Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients. ( 29338319 )	Matboli M....Abdel-Rahman O.	2018
25	Variation in incidence trends of malignant pleural mesothelioma in Europe. ( 29437947 )	Ahmed M....Breen D.	2018
26	Malignant Pleural Mesothelioma: The Last 8 Years of Experience in Our Area. ( 29804950 )	BenA-tez J.C....BastA_s R.	2018
27	Single-institution experience of intensity-modulated radiotherapy for malignant pleural mesothelioma at University of Catania. ( 29400553 )	Spatola C....Privitera G.	2018
28	Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. ( 29399399 )	Riganti C....Taulli R.	2018
29	Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma. ( 29921948 )	Xu D....Peng R.W.	2018
30	Is there a role for immunotherapy in malignant pleural mesothelioma? ( 29845408 )	Tartarone A....Aieta M.	2018
31	Revised Modified RECIST Criteria in Malignant Pleural Mesothelioma (Version 1.1): A Step Forward in a Long Race. ( 29935841 )	Tsao A.S....Gill R.R.	2018
32	Breast Metastasis from Malignant Pleural Mesothelioma: A Rare Challenging Entity. ( 29935848 )	Catino A....Galetta D.	2018
33	Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience. ( 29367501 )	Miyazaki T....Nagayasu T.	2018
34	Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma. ( 29742520 )	Maller B....Tanvetyanon T.	2018
35	Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. ( 29804728 )	Mansfield A.S....Symanowski J.T.	2018
36	Proton beam therapy for malignant pleural mesothelioma. ( 29876318 )	Badiyan S.N....Simone C.B.	2018
37	Focal Adhesion Kinase a Potential Therapeutic Target for Pancreatic Cancer and Malignant Pleural Mesothelioma. ( 29303405 )	Kanteti R....Salgia R.	2018
38	<i>SFRP</i> Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma. ( 29386699 )	Cheng Y.Y....Reid G.	2017
39	Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma. ( 28027772 )	Kanemura S....Nakano T.	2017
40	Percutaneous Cryoablation for the Treatment of Recurrent Malignant Pleural Mesothelioma: Safety, Early-Term Efficacy, and Predictors of Local Recurrence. ( 27979596 )	Abtin F....Cameron R.B.	2017
41	Radiotherapy for the treatment of malignant pleural mesothelioma. ( 28884702 )	Perrot M....Cho B.C.J.	2017
42	Open access phone triage for veterans with suspected malignant pleural mesothelioma. ( 27979465 )	Siegert C.J....Lebenthal A.	2017
43	Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). ( 28862644 )	Klampatsa A....Albelda S.M.	2017
44	Clinical staging of malignant pleural mesothelioma: current perspectives. ( 28860886 )	Bonomi M....Ceresoli G.L.	2017
45	Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma. ( 28197626 )	Cregan S....Gray S.G.	2017
46	BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma. ( 27771374 )	M McGregor S....Krausz T.	2017
47	Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma. ( 28948332 )	Vigneswaran W.T....Husain A.N.	2017
48	Prognostic and predictive role of [(18) F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. ( 28941158 )	Zucali P.A....Santoro A.	2017
49	The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review. ( 28859932 )	Ashton M....Chalmers A.	2017
50	Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma. ( 29371938 )	Hylebos M....Op de Beeck K.	2017

Sources

Genes for Malignant Pleural Mesothelioma

Genes related to Malignant Pleural Mesothelioma (0 elite genes):

(show all 22)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	PVT1	Pvt1 Oncogene Our results suggest that C-MYC and PVT1 CNG promotes a malignant phenotype of MPM,with C-MYC CNG stimulating cell proliferation and PVT1 both stimulating proliferation and inhibiting apoptosis. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	160.5	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	24926545
2	GAS5	Growth Arrest Specific 5 GAS5 expression was lower in MPM cell linecompared to normal mesothelial cells. GAS5 was upregulated upon growth arrest induced by inhibition of Hedgehog and PI3K/mTOR signalling in in vitro MPM models. The increase in GAS5 lncRNA was accompanied by increased promoter activity. Silencing of GAS5 increased the expression of glucocorticoid responsive genes glucocorticoid inducible leucine-zipper and serum/glucocorticoid-regulated kinase-1 and shortened the length of the cell cycle. Drug induced growth arrest was associated with GAS5 accumulation in the nuclei. GAS5 was abundant in tumoral quiescent cells and it was correlated to podoplanin expression. Dysfunction Pattern: Regulation [down-regulated]	RNA Gene	156.95	Experimental evidence: Regulation ³⁹ GeneCards inferred via : Publications (show sections)	24885398
3	LINC00535	Long Intergenic Non-Protein Coding RNA 535 AK130977 and AX746718 were both found to be down-regulated via both microarray and RT-qPCR (AK130977 Microarray (MA) = -5.207,RT-qPCR = -1.6, AX746718 MA = -3.37,RT-qPCR = -4.6),with AK130977 demonstrating fairly small changes using RT-qPCR. Similarly,BX648695,AK129685,EF177379,AK054908,AK130275,AF268386 and NR_003584 all demonstrated consistent up-regulation using both microarrays and RT-qPCR. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	150	Experimental evidence: Regulation ³⁹	23976967
4	ENSG00000261211	AK130977 and AX746718 were both found to be down-regulated via both microarray and RT-qPCR (AK130977 Microarray (MA) = -5.207,RT-qPCR = -1.6, AX746718 MA = -3.37,RT-qPCR = -4.6),with AK130977 demonstrating fairly small changes using RT-qPCR. Similarly,BX648695,AK129685,EF177379,AK054908,AK130275,AF268386 and NR_003584 all demonstrated consistent up-regulation using both microarrays and RT-qPCR. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	150	Experimental evidence: Regulation ³⁹	23976967
5	SNHG8	Small Nucleolar RNA Host Gene 8 AK130977 and AX746718 were both found to be down-regulated via both microarray and RT-qPCR (AK130977 Microarray (MA) = -5.207,RT-qPCR = -1.6, AX746718 MA = -3.37,RT-qPCR = -4.6),with AK130977 demonstrating fairly small changes using RT-qPCR. Similarly,BX648695,AK129685,EF177379,AK054908,AK130275,AF268386 and NR_003584 all demonstrated consistent up-regulation using both microarrays and RT-qPCR. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	150	Experimental evidence: Regulation ³⁹	23976967
6	ENSG00000258561	AK130977 and AX746718 were both found to be down-regulated via both microarray and RT-qPCR (AK130977 Microarray (MA) = -5.207,RT-qPCR = -1.6, AX746718 MA = -3.37,RT-qPCR = -4.6),with AK130977 demonstrating fairly small changes using RT-qPCR. Similarly,BX648695,AK129685,EF177379,AK054908,AK130275,AF268386 and NR_003584 all demonstrated consistent up-regulation using both microarrays and RT-qPCR. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	150	Experimental evidence: Regulation ³⁹	23976967
7	SNHG7	Small Nucleolar RNA Host Gene 7 AK130977 and AX746718 were both found to be down-regulated via both microarray and RT-qPCR (AK130977 Microarray (MA) = -5.207,RT-qPCR = -1.6, AX746718 MA = -3.37,RT-qPCR = -4.6),with AK130977 demonstrating fairly small changes using RT-qPCR. Similarly,BX648695,AK129685,EF177379,AK054908,AK130275,AF268386 and NR_003584 all demonstrated consistent up-regulation using both microarrays and RT-qPCR. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	150	Experimental evidence: Regulation ³⁹	23976967
8	POT1-AS1	POT1 Antisense RNA 1 AK130977 and AX746718 were both found to be down-regulated via both microarray and RT-qPCR (AK130977 Microarray (MA) = -5.207,RT-qPCR = -1.6, AX746718 MA = -3.37,RT-qPCR = -4.6),with AK130977 demonstrating fairly small changes using RT-qPCR. Similarly,BX648695,AK129685,EF177379,AK054908,AK130275,AF268386 and NR_003584 all demonstrated consistent up-regulation using both microarrays and RT-qPCR. Dysfunction Pattern: Regulation [up-regulated]	RNA Gene	150	Experimental evidence: Regulation ³⁹	23976967
9	SPP1	Secreted Phosphoprotein 1	Protein Coding	30.9	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17493236 19528482 17504993 (more) 16221779 18550471 16911785 19634115 18670302
10	TYMS	Thymidylate Synthetase	Protein Coding	29.46	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	20177021 17333344
11	NKX2-1	NK2 Homeobox 1	Protein Coding	29.17	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	15614737 11234300 17279584 (more) 9500194 16415794 19152187 18051806 10757409 11956814
12	BIRC5	Baculoviral IAP Repeat Containing 5	Protein Coding	28.33	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	12479365 18827603
13	WT1	Wilms Tumor 1	Protein Coding	28.02	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	19516197 10759948 16415794 (more) 10757409 19152187
14	THBD	Thrombomodulin	Protein Coding	28.02	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9253621 1357974 10697265 (more) 9414183 12383211 19152187
15	MSLN	Mesothelin	Protein Coding	26.78	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	19201924 16415794 18670302 (more) 18394747 20075387 17504993 17646232 19302997
16	CDH2	Cadherin 2	Protein Coding	25.78	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	10227598 8522310 9190996
17	XIAP	X-Linked Inhibitor Of Apoptosis	Protein Coding	24.75	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17350081
18	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	24.5	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9692834
19	BAP1	BRCA1 Associated Protein 1	Protein Coding	24.41	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	CALB2	Calbindin 2	Protein Coding	24.29	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	10697265 17279584 9796717 (more) 10595711 10759948 15736446 19152187 14976533 18051806 12383211 16415794
21	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	23.97	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	2328062 9639123 12940775
22	EFEMP1	EGF Containing Fibulin Extracellular Matrix Protein 1	Protein Coding	23.56	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Malignant Pleural Mesothelioma

Copy number variations for Malignant Pleural Mesothelioma from CNVD:

⁷ (show all 35)

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	13406	1	1	2300000	Loss		Pleural malignant mesothelioma
2	21839	1	16200000	28000000	Loss		Pleural malignant mesothelioma
3	33951	1	50700000	61300000	Amplification		Pleural malignant mesothelioma
4	35953	1	69700000	116100000	Loss		Pleural malignant mesothelioma
5	35955	1	69700000	116100000	Loss	CLCA1	Pleural malignant mesothelioma
6	35957	1	69700000	116100000	Loss	CLCA2	Pleural malignant mesothelioma
7	35959	1	69700000	116100000	Loss	CLCA3	Pleural malignant mesothelioma
8	35961	1	69700000	116100000	Loss	CLCA4	Pleural malignant mesothelioma
9	35963	1	69700000	116100000	Loss	COL11A1	Pleural malignant mesothelioma
10	35965	1	69700000	116100000	Loss	TGFBR3	Pleural malignant mesothelioma
11	35967	1	69700000	120600000	Loss		Pleural malignant mesothelioma
12	37057	1	84900000	107200000	Loss		Pleural malignant mesothelioma
13	69953	12	56600000	58100000	Gain		Pleural malignant mesothelioma
14	75173	13	17900000	45800000	Loss	BRCA2	Pleural malignant mesothelioma
15	85739	14	50900000	107349540	Loss	CCNK	Pleural malignant mesothelioma
16	85741	14	50900000	107349540	Loss	CDKN3	Pleural malignant mesothelioma
17	113646	17	44900000	81195210	Gain	ERN1	Pleural malignant mesothelioma
18	113648	17	44900000	81195210	Gain	MAP3K3	Pleural malignant mesothelioma
19	113650	17	44900000	81195210	Gain	PRKCA	Pleural malignant mesothelioma
20	113652	17	44900000	81195210	Gain	SMARCD2	Pleural malignant mesothelioma
21	175423	3	39400000	63700000	Loss	CACNA2D3	Pleural malignant mesothelioma
22	175425	3	39400000	63700000	Loss	CTNNB1	Pleural malignant mesothelioma
23	175427	3	39400000	63700000	Loss	MLH1	Pleural malignant mesothelioma
24	175772	3	44100000	44200000	Loss		Pleural malignant mesothelioma
25	187515	4	50400000	191154276	Loss		Pleural malignant mesothelioma
26	191706	5	1	48400000	Gain		Pleural malignant mesothelioma
27	204730	6	114600000	118300000	Loss	HDAC2	Pleural malignant mesothelioma
28	204732	6	114600000	118300000	Loss	MARCKS	Pleural malignant mesothelioma
29	217076	7	1	4500000	Gain		Pleural malignant mesothelioma
30	234872	8	139900000	146364022	Gain		Pleural malignant mesothelioma
31	250027	9	19900000	25600000	Loss	C9orf14	Pleural malignant mesothelioma
32	250030	9	19900000	25600000	Loss	CDKN2A	Pleural malignant mesothelioma
33	250032	9	19900000	25600000	Loss	CDKN2B	Pleural malignant mesothelioma
34	250070	9	19900000	33200000	Loss		Pleural malignant mesothelioma
35	251885	9	33200000	36300000	Gain		Pleural malignant mesothelioma

Sources

Expression for Malignant Pleural Mesothelioma

Search GEO for disease gene expression data for Malignant Pleural Mesothelioma.

Sources

Pathways for Malignant Pleural Mesothelioma

Pathways related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	FGF signaling pathway ¹	10.47	CDH2 MET SPP1

Sources

GO Terms for Malignant Pleural Mesothelioma

Biological processes related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	inhibition of cysteine-type endopeptidase activity involved in apoptotic process	GO:1990001	8.96	BIRC5 XIAP
2	regulation of signal transduction	GO:0009966	8.8	BIRC5 CDH2 XIAP

Sources

Sources for Malignant Pleural Mesothelioma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia